2-(2,3-二氢-1,4-苯并二噁英-2-基)-1,3-噻唑-4-羧酸 | 175203-34-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2-(2,3-二氢-1,4-苯并二噁英-2-基)-1,3-噻唑-4-羧酸
• 英文名称: BI-9C1
• 英文别名: 2-(2,3-Dihydro-1,4-benzodioxin-2-YL)-1,3-thiazole-4-carboxylic acid；2-(2,3-dihydro-1,4-benzodioxin-3-yl)-1,3-thiazole-4-carboxylic acid
• CAS: 175203-34-6
• 化学式: C₁₂H₉NO₄S
• mdl: MFCD00084891
• 分子量: 263.274
• InChiKey: OTPNRLRDUARFBI-UHFFFAOYSA-N

物化性质

• 沸点：
  476.6±45.0 °C(Predicted)
• 密度：
  1.480±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  96.9
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934100090

SDS

Name:	2-(2 3-Dihydro-1 4-benzodioxin-2-yl)-1 3-thiazole-4-carboxylic acid Material Safety Data Sheet
Synonym:
CAS:	175203-34-6

Section 1 - Chemical Product MSDS Name:2-(2 3-Dihydro-1 4-benzodioxin-2-yl)-1 3-thiazole-4-carboxylic acid Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175203-34-6	2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-1	90+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175203-34-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 193 - 198 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H9NO4S
Molecular Weight: 263.27

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175203-34-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-1,3-thiazole-4-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 175203-34-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175203-34-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175203-34-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(2,3-二氢-1,4-苯并二噁英-2-基)-1,3-噻唑-4-羧酸 在 盐酸 、 三乙酰氧基硼氢化钠 、 1-羟基苯并三唑 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 为溶剂， 生成 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-N-[[(3S)-1-(naphthalen-1-ylmethyl)piperidin-3-yl]methyl]-1,3-thiazole-4-carboxamide
  参考文献：
  名称：

  Discovery of 2-Aminothiazole-4-carboxamides, a Novel Class of Muscarinic M3 Selective Antagonists, through Solution-Phase Parallel Synthesis

  摘要：

  描述了一类新的选择性抗美洲豹M3受体拮抗剂的合成和结构-活性关系。在寻找一种结构与2-(4,4-二氟环戊基)-2-苯乙酰胺衍生物不同的抗美洲豹M3受体拮抗剂的过程中，我们在内部化学库中识别出了一种噻唑-4-氨基甲酸酯衍生物（1）作为领先化合物。由于该化合物（1）在人体结合实验中对M3受体的结合亲和力较低（Ki=140 nM），我们尝试通过组合化学方法对1进行衍生化，以提高其对M3受体的效能和对M1及M2受体的选择性。溶液相平行合成有效地促进了1的每个片段的优化。因此，我们识别出环辛烯基甲基衍生物（3e）和环壬烯基甲基衍生物（3f）作为该类抗美洲豹M3受体选择性拮抗剂的代表。

  DOI：

  10.1248/cpb.53.437
• 作为产物：
  描述：

  1,4-苯并二氧六环-2-甲酰胺 在 sodium hydroxide 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 2-(2,3-二氢-1,4-苯并二噁英-2-基)-1,3-噻唑-4-羧酸
  参考文献：
  名称：

  Discovery of 2-Aminothiazole-4-carboxamides, a Novel Class of Muscarinic M3 Selective Antagonists, through Solution-Phase Parallel Synthesis

  摘要：

  描述了一类新的选择性抗美洲豹M3受体拮抗剂的合成和结构-活性关系。在寻找一种结构与2-(4,4-二氟环戊基)-2-苯乙酰胺衍生物不同的抗美洲豹M3受体拮抗剂的过程中，我们在内部化学库中识别出了一种噻唑-4-氨基甲酸酯衍生物（1）作为领先化合物。由于该化合物（1）在人体结合实验中对M3受体的结合亲和力较低（Ki=140 nM），我们尝试通过组合化学方法对1进行衍生化，以提高其对M3受体的效能和对M1及M2受体的选择性。溶液相平行合成有效地促进了1的每个片段的优化。因此，我们识别出环辛烯基甲基衍生物（3e）和环壬烯基甲基衍生物（3f）作为该类抗美洲豹M3受体选择性拮抗剂的代表。

  DOI：

  10.1248/cpb.53.437

文献信息

• A new polymer-bound N-hydroxysuccinimidyl active ester linker
  作者：Hui Shao、Qiang Zhang、Robert Goodnow、Li Chen、Steve Tam

  DOI：10.1016/s0040-4039(00)00619-5

  日期：2000.6

  Synthesis of a new N-hydroxysuccinimidyl resin is described and the N-acylation with this resin provides amide products in high yields and excellent purities. This new linker is suitable for combinatorial library synthesis.

  描述了新的N-羟基琥珀酰亚胺树脂的合成，并且用该树脂进行N-酰化提供了高收率和优异纯度的酰胺产物。这个新的链接器适用于组合库综合。
• PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF
  申请人：GE Yu

  公开号：US20140162998A1

  公开（公告）日：2014-06-12

  A Pim kinase inhibitor compound having the structure represented by Formula I, and isomers, diastereomers, enantiomers, tautomers, and pharmaceutically acceptable salts thereof. The compounds significantly inhibit Pim kinase activity and can be used to prepare drugs for treating Pim kinase mediated diseases, such as cancers, autoimmune diseases, allergic reactions, or organ transplant rejection. Also provided are methods for preparing the compounds represented by Formula I.

  一种具有由化学式I表示的结构的Pim激酶抑制剂化合物，以及其异构体、对映异构体、对映体、互变异构体和药学上可接受的盐。这些化合物显著抑制Pim激酶活性，可用于制备用于治疗Pim激酶介导疾病的药物，如癌症、自身免疫疾病、过敏反应或器官移植排斥。还提供了制备由化学式I表示的化合物的方法。
• Protease inhibitors
  申请人：Bondinell E William

  公开号：US20060052365A1

  公开（公告）日：2006-03-09

  This invention relates 4-amino-azepan-3-ones of formula (I) which are useful as protease inhibitors, particularly of cathepsin S, and as such are useful for preventing a number of diseases amongst which are atherosclerotic lesions and pulmonary diseases such as asthma and allergic reactions.

  这项发明涉及式（I）的4-氨基-氮杂七环-3-酮，它们可用作蛋白酶抑制剂，特别是卡特普辛S的抑制剂，并且作为预防多种疾病的有用药物，其中包括动脉粥样硬化病变和肺部疾病，如哮喘和过敏反应。
• Pyrazoles as inhibitors of tumor necrosis factor
  申请人：Borcherding R. David

  公开号：US20060063796A1

  公开（公告）日：2006-03-23

  The present invention provides compounds of Formula (I) and ester prodrugs, pharmaceutically acceptable salts or solvates of such compounds; or ester prodrugs of such salts or solvates; pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF).

  本发明提供了式（I）的化合物和酯前药、这些化合物的药学上可接受的盐或溶剂；或这些盐或溶剂的酯前药；包括这些化合物的制药组合物，其制备以及它们在治疗能够通过抑制p38激酶和/或肿瘤坏死因子（TNF）调节的疾病状态中的药物应用。
• プロテアーゼ阻害剤
  申请人：スミスクライン・ビーチャム・コーポレイション

  公开号：JP2006505526A

  公开（公告）日：2006-02-16

  本発明は、プロテアーゼ阻害剤、特に、カテプシンＳの阻害剤として、およびアテローム性領域における多くの疾患および喘息およびアレルギー反応のような肺疾患の予防に有用な式（Ｉ）： 【化１】で示される４−アミノ−アゼパン−３−オンに関する。

  本发明涉及蛋白酶抑制剂，特别是符合式（I）的 4-氨基氮杂环庚烷：[化学式 1]，可作为 cathepsin S 的抑制剂，用于预防动脉粥样硬化区域的多种疾病和肺部疾病，如哮喘和过敏反应。-3-酮，涉及。